Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study

por Liu, Jing, Liu, Xiaohong, Jia, Jinsong, Gong, Lizhong, Lu, Shengye, Wang, Jing, Huang, Xiao-jun, Jiang, Hao
Publicado 2022